Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients

Experimental Dermatology

Volumn 13, Issue 5, 2004, Pages 298-304

  Weisshaar, Elke ^a,b   Dunker, Nadine ^a   Röhl, Friedrich Wilhelm ^a   Gollnick, Harald ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cetirizine; Haemodialysis; Itch; Ondansetron; Tropisetron

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; HISTAMINE; ONDANSETRON; SEROTONIN; SEROTONIN ANTAGONIST; TROPISETRON;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IONTOPHORESIS; KIDNEY FAILURE; MALE; PRURITUS; RASH; SKIN TEMPERATURE; URTICARIA; VOLUNTEER;

ADULT; AGED; ANTIPRURITICS; CETIRIZINE; FEMALE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; INDOLES; IONTOPHORESIS; KIDNEY FAILURE; MALE; MIDDLE AGED; ONDANSETRON; PRURITUS; RECEPTORS, SEROTONIN, 5-HT3; REFLEX; RENAL DIALYSIS; SEROTONIN; SEROTONIN ANTAGONISTS; SKIN; SKIN TEMPERATURE; TREATMENT OUTCOME;

EID: 2642517023     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2004.00184.x     Document Type: Article

References (23)

1. Ståhle-Bäckdahl M. Uremic pruritus: clinical and experimental studies. Acta Derm Venereol 1989: (Suppl. 145): 7-38.
2. Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001: 81: 108-111.
3. Mettang T, Pauli-Magnus C, Alscher D A. Uraemic pruritus - new perspectives and insights from recent trials. Nephrol Dial Transplant 2002: 17: 1558-1563.
4. Gilchrest B A, Stern R S, Steinman T I, Brown R, Arendt K, Anderson W. Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 1982: 118: 154-156.
5. Subach R A, Marx M A. Evaluation of uremic pruritus at an outpatient hemodialysis unit. Ren Fail 2002: 24: 609-614.
6. Urbonas A, Schwartz R A, Szepietowski J C. Uremic pruritus - an update. Am J Nephrol 2001: 21: 343-350.
7. Merkus M P, Jager K J, Dekker F W, de Haan R J, Boeschoten E W, Krediet R T for the NECOSAD Study Group. Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant 1999: 14: 1163-1170.
8. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998: 338: 1428-1437.
9. Weisshaar E, Kucenic M J, Fleischer A B, Pruritus. A review. Acta Derm Venereol 2003: (Suppl. 213): 5-32.
10. Kerr P G, Argiles A, Mion C. Whole blood serotonin levels are markedly elevated in patients on dialytic therapy. Am J Nephrol 1992: 12: 14-18.
11. Balaskas E V, Bamihas G I, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998: 78: 595-402.
12. Weisshaar E, Dunker N, Domröse U, Neumann K H, Gollnick H. Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistamine therapy. Clin Nephrol 2003: 59: 124-129.
13. Schwörer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Invest 1993: 71: 659-662.
14. Andrews P A, Quan V, Ogg C S. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995: 10: 140.
15. Ashmore S D, Jones C H, Newstead C G, Daly M J, Chrystin H. Ondansetron therapy for uremic patients in hemodialysis. Am J Kidney Dis 2000: 35: 827-831.
16. Murphy M, Reaich D, Pai P, Finns P, Carmichael A J. A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003: 148: 314-317.
17. Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally induced itch? Inflamm Res 1997: 46: 412-416.
18. Weisshaar E, Ziethen B, Röhl F W, Gollnick H. The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion - an experimental study. Exp Dermatol 1999: 8: 254-260.
19. Albares M P, Betlock I, Guijarro I, Vegara G, Pascual J C, Botella R. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 2003: 148: 376-377.
20. Estelle F, Simons R, Simons K J. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999: 36 (5): 329-352.
21. Bayramgürler D, Bilen N, Apaydýn R et al. Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses. Clin Exp Dermatol 1999: 24: 401-406.
22. Grant J A, Danielson L, Rihoux J P, DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare resonse for 24 h in healthy male subjects. Allergy 1999: 54: 700-707.
23. Aubia J, Aguilera J, Llorach I et al. Dialysis pruritus: effect of cimetidine. J Dial 1980: 4: 141-145.